Table 3.
Characterization of ODNP efficacy and reaction kinetics of HSA-NIT conjugates after proteolysis.
| Sample | A 1 | A 2 | τ1 [1/h] | τ2 [1/h] | P1/2 [W] | |Emax| |
|---|---|---|---|---|---|---|
| HSA-Me-mal C * | −7.4 ± 0.1 | −7.2 ± 0.1 | 6.9 ± 0.2 | 0.9 ± 0.1 | 10.8 ± 1.2 | 54 ± 3 |
| HSA-Me/Me-mal C | −5.7 ± 0.3 | −8.4 ± 0.3 | 8.3 ± 0.9 | 1.4 ± 0.1 | 10.3 ± 1.2 | 50 ± 3 |
| HSA-Me/Me-mal T | −8.7 ± 0.4 | −4.0 ± 0.5 | 2.8 ± 0.2 | 0.5 ± 0.1 | 10.9 ± 1.1 | 47 ± 2 |
| HSA-Et-mal C | −2.8 ± 0.1 | −3.9 ± 0.3 | 18.2 ± 7.4 | 2.7 ± 0.3 | 22.6 ± 3.9 | 45 ± 5 |
| HSA-Et/Et-mal C | −6.2 ± 0.1 | – | 3.9 ± 0.1 | – | 21.2 ± 4.0 | 39 ± 5 |
| HSA-Et/Et-mal T | −2.4 ± 0.1 | −3.6 ± 0.1 | 6.9 ± 0.6 | 1.4 ± 0.1 | 24.3 ± 3.1 | 42 ± 3 |
* The sample name has been extended to include the type of protease, either C or T, for which the reaction kinetics were monitored.